For all the success that drug-eluting stents (DES) have had in preventing restenosis, there is increasing data showing that in a small number of patients, these implants also can produce significant adverse events resulting from late-stage thrombosis. To address that problem, Medtronic Inc. has gained rights to ReVas, a drug development program based on novel targets of vascular inflammation, from Resverlogix Inc.
Donald J. McCaffrey, president and CEO of Calgary, Alberta-based Resverlogix, points out that the two DES currently approved for US...